Oulu University Hospital is a university hospital in Oulu, Finland. It is the northernmost of the five university hospitals in Finland. The Oulu University Hospital is affiliated with the University of Oulu, and it is used as a teaching hospital by the Faculty of Medicine. The hospital was established in 1973.

During the past decade, Oulun yliopistollinen sairaala conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 4 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 1 clinical trials were completed. i.e. 12.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Oulun yliopistollinen sairaala" #1 sponsor was "Bayer" with 5 trials, followed by "Pfizer" with 4 trials sponsored, "Boehringer Ingelheim" with 2 trials sponsored, "Amgen" with 1 trials sponsored and "Hinova Pharmaceuticals USA, Inc." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oulun yliopistollinen sairaala" #1 collaborator was "Astellas Pharma Inc" with 4 trials as a collaborator and "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 3 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Oulun yliopistollinen sairaala" are "Prostate Cancer" (3 trials), "Cancer of the Prostate" (2 trials), "Atrial Fibrillation" (1 trials), "Bronchopulmonary Dysplasia" (1 trials) and "Cancer" (1 trials). Many other conditions were trialed in "Oulun yliopistollinen sairaala" in a lesser frequency.

Most popular intervention types in "Oulun yliopistollinen sairaala" are "Drug" (14 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Enzalutamide" (4 trials), "Prednisone" (2 trials), "Abiraterone" (1 trials) and "Apixaban" (1 trials). Other intervention names were less common.

The vast majority of trials in "Oulun yliopistollinen sairaala" are 7 trials for "All" genders and 7 trials for "Male" genders.

Currently, there are NaN active trials in "Oulun yliopistollinen sairaala". undefined are not yet recruiting, 4 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Oulun yliopistollinen sairaala, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Oulun yliopistollinen sairaala, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".